Recently, several studies performed in animal models and in human clinical trials for the management of dyslipidemia have focused on the development of pharmacological inhibitors of ANGPTL3, such as monoclonal antibodies for blocking ANGPTL3 activity and antisense oligonucleotides (ASOs) for reducing ANGPTL3 protein expression. This evidence concerns the gene ANGPTL3 and metabolic syndrome.